Abstract 178P
Background
Liquid biopsy (LBx) based comprehensive genomic profiling (CGP) is increasingly used in clinical practice. The sensitivity of LBx is influenced by levels of circulating tumor DNA (ctDNA), but limited data is available correlating ctDNA levels with clinical parameters and their effect on detecting distinct genomic alterations in metastatic colorectal cancer (mCRC).
Methods
LBx using FoundationOne Liquid CDx was performed on plasma ctDNA at baseline in patients with RAS/BRAFV600E wild type (WT) mCRC enrolled in the CAPRI-2 GOIM trial.
Results
Among 205 patients with available baseline LBx, median ctDNA tumor fraction (TF) was 25% (range, 0.1-86%). ctDNA TF was higher among patients presenting with isolated liver involvement (n=68, ctDNA 34.5% [IQR 15.0-54.2]) or liver with other metastatic sites (n=90, ctDNA 30.0% [IQR 9.2-56.3]) as compared to those showing only lung (n=11, ctDNA 1.3% [IQR 1.0-2.3]; P<0.001) or lymph nodes involvement (n=13, ctDNA 1.7% [IQR 1.23-37.5]; P<0.001). ctDNA TF positively correlated with higher number of metastatic sites (≥3 anatomical sites: ctDNA 51% [IQR 17-66.5] vs. 1-2 sites: ctDNA 22% [IQR 2.3-49]; P<0.001), albeit only liver involvement (P<0.001) but not the number of anatomical sites (P=0.16) associated with higher ctDNA TF in the multivariable model. Samples showing copy number variants (CNV) showed higher ctDNA TF (LBx amplifications (n=64): ctDNA 45% [IQR 25-58.8] vs. 16% [IQR 1.7-48.5]; P<0.001; LBx deletions (n=12): ctDNA 56% [IQR 46.8-68.2] vs. 25% [IQR 3.3-51.0]; P<0.001), with no deletions and only 4 amplifications detected among samples showing a ctDNA TF below 10%. Patients showing a high Tumor mutational burden (TMB) (n=20) showed a numerical higher ctDNA TF (ctDNA 37.5% [IQR 16.5 vs. 56.4] vs. 28% [IQR 4.05-51.2]; P=0.08), with only one TMB-high case showing a ctDNA TF below 10%.
Conclusions
ctDNA levels depend on metastatic sites, with significantly lower levels in patients without liver involvement. Distinct alteration classes exhibit distinct analytical sensitivity, with CNV requiring higher ctDNA levels for detection.
Editorial acknowledgement
Clinical trial identification
EudraCT 2020-003008-15; NCT05312398.
Legal entity responsible for the study
The authors.
Funding
The CAPRI 2-GOIM clinical trial is partially supported by a research grant from Merck KGaA Italy.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
94P - Clinical utility of long read sequencing for comprehensive analysis of cancer patient genomes
Presenter: Rowan Howell
Session: Cocktail & Poster Display session
Resources:
Abstract
95P - Implementation of TDM and PGx in mRCC patients treated with sunitinib to personalize drug dosing
Presenter: Giorgia Bortolus
Session: Cocktail & Poster Display session
Resources:
Abstract
96P - Physician perceptions and the evolving landscape of next generation sequencing (NGS) use across EU4+UK
Presenter: Keerun Khela
Session: Cocktail & Poster Display session
Resources:
Abstract
97P - Population-based assessment of outcomes in pancreatic ductal adenocarcinoma (PDAC) patients (pts) with pathogenic germline variants (PGVs)
Presenter: Phoebe Cheng
Session: Cocktail & Poster Display session
Resources:
Abstract
98P - Clinical implementation of NGS and ESCAT for optimized cancer therapy
Presenter: AI. Martin-Quesada
Session: Cocktail & Poster Display session
Resources:
Abstract
99P - Prevalence of homologous recombination repair deficiency-associated variants in non-selected Portuguese patients with metastatic prostate cancer
Presenter: Tiago Barroso
Session: Cocktail & Poster Display session
Resources:
Abstract
100P - Real-world insights in precision oncology: First data of the comprehensive clinico-genomics database network AIO-BNHO-CONNECT (AIO-TF-0122) in Germany
Presenter: Maike Collienne
Session: Cocktail & Poster Display session
Resources:
Abstract
101P - Molecular tumor board for advanced cancer patients offers new therapeutic opportunities beyond level 1 ESCAT scale
Presenter: Victor Segui-Manzaneque
Session: Cocktail & Poster Display session
Resources:
Abstract
102P - Prognostic model of pediatric AML patients with RUNX1-RUNX1T1 fusion gene
Presenter: Yang Xun
Session: Cocktail & Poster Display session
Resources:
Abstract
103P - NICE recommendations and ESMO-MCBS/ESCAT scores for solid tumour drugs
Presenter: Eunice Xing
Session: Cocktail & Poster Display session
Resources:
Abstract